Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 13Thoracic 2Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Adrenocortical Carcinoma 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × antineoplaston A10 × Endocrine × Clear all
NCT00003453 2018-05-09

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Burzynski Research Institute

Phase 2 Terminated
6 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡